A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide
Contact Name: James Nasman
Please contact NasmanJ@sutterhealth.org about study OCEAN OP-103
Location: REDI (East Bay)View study details on ClinicalTrials.gov
February 01, 2019
Investigator: Ellis C. Dillon, Ph.D.
Investigator: Su-Ying Liang, Ph.D.